Patient Square Capital LP Purchases Shares of 151,833 Abivax SA Sponsored ADR $ABVX

Patient Square Capital LP purchased a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 151,833 shares of the company’s stock, valued at approximately $12,891,000. Abivax makes up 3.4% of Patient Square Capital LP’s holdings, making the stock its 4th biggest position. Patient Square Capital LP owned approximately 0.20% of Abivax as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the stock. First Horizon Corp bought a new position in shares of Abivax during the 3rd quarter valued at approximately $36,000. Hantz Financial Services Inc. purchased a new position in Abivax during the third quarter valued at approximately $52,000. Covestor Ltd bought a new position in shares of Abivax in the third quarter worth approximately $96,000. Moody Aldrich Partners LLC purchased a new stake in shares of Abivax in the third quarter worth $207,000. Finally, Ashton Thomas Securities LLC bought a new stake in shares of Abivax during the 3rd quarter valued at $212,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ABVX has been the subject of a number of analyst reports. Citigroup reiterated a “market outperform” rating on shares of Abivax in a research note on Thursday, January 8th. Oppenheimer set a $131.00 price objective on Abivax in a research note on Thursday, January 8th. Wolfe Research upgraded Abivax to a “strong-buy” rating in a research report on Thursday, November 6th. Wall Street Zen cut Abivax from a “hold” rating to a “sell” rating in a report on Saturday, December 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.00.

Abivax Trading Up 0.1%

Shares of ABVX stock opened at $130.35 on Monday. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The stock has a market capitalization of $10.31 billion, a price-to-earnings ratio of -31.18 and a beta of 0.81. Abivax SA Sponsored ADR has a 12-month low of $4.77 and a 12-month high of $148.83. The stock’s 50-day moving average price is $123.15 and its 200-day moving average price is $104.40.

Abivax (NASDAQ:ABVX) last announced its quarterly earnings results on Monday, December 15th. The company reported ($2.46) EPS for the quarter. The company had revenue of ($4.92) million during the quarter. Equities research analysts predict that Abivax SA Sponsored ADR will post -2.83 EPS for the current fiscal year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.